Copyright
©The Author(s) 2004.
World J Gastroenterol. Aug 15, 2004; 10(16): 2379-2382
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Published online Aug 15, 2004. doi: 10.3748/wjg.v10.i16.2379
Figure 5 Overall reduction rates of symptoms among patients treated with cetraxate (600 mg, t.
i.d.) or DA-9601 (180 mg and 360 mg, t.i.d.) for 2 wk.
- Citation: Seol SY, Kim MH, Ryu JS, Choi MG, Shin DW, Ahn BO. DA-9601 for erosive gastritis: Results of a double-blind placebo-controlled phase III clinical trial. World J Gastroenterol 2004; 10(16): 2379-2382
- URL: https://www.wjgnet.com/1007-9327/full/v10/i16/2379.htm
- DOI: https://dx.doi.org/10.3748/wjg.v10.i16.2379